| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteosarcoma | 83 | 2021 | 920 | 12.110 |
Why?
|
| Bone Neoplasms | 64 | 2021 | 2559 | 6.670 |
Why?
|
| Sarcoma, Ewing | 32 | 2019 | 406 | 6.220 |
Why?
|
| fas Receptor | 22 | 2020 | 185 | 6.030 |
Why?
|
| Acetylmuramyl-Alanyl-Isoglutamine | 36 | 2013 | 58 | 3.320 |
Why?
|
| Fas Ligand Protein | 11 | 2020 | 152 | 2.950 |
Why?
|
| Phosphatidylethanolamines | 30 | 2013 | 63 | 2.850 |
Why?
|
| Lung Neoplasms | 54 | 2021 | 11571 | 2.480 |
Why?
|
| Pericytes | 9 | 2013 | 96 | 2.380 |
Why?
|
| Interleukin-12 | 11 | 2017 | 255 | 2.040 |
Why?
|
| Monocytes | 44 | 1999 | 771 | 1.990 |
Why?
|
| Neovascularization, Pathologic | 15 | 2013 | 1545 | 1.910 |
Why?
|
| Vascular Endothelial Growth Factor A | 10 | 2011 | 1534 | 1.810 |
Why?
|
| Cardiotoxicity | 4 | 2023 | 158 | 1.740 |
Why?
|
| Bone Marrow Cells | 11 | 2013 | 939 | 1.680 |
Why?
|
| Mice, Nude | 41 | 2021 | 4303 | 1.670 |
Why?
|
| Sarcoma | 7 | 2023 | 1725 | 1.630 |
Why?
|
| Doxorubicin | 21 | 2023 | 3005 | 1.390 |
Why?
|
| Mice | 88 | 2023 | 34393 | 1.370 |
Why?
|
| DNA Topoisomerases, Type II | 11 | 2005 | 117 | 1.290 |
Why?
|
| Cytotoxicity, Immunologic | 33 | 1999 | 673 | 1.280 |
Why?
|
| Antibiotics, Antineoplastic | 6 | 2023 | 724 | 1.270 |
Why?
|
| Interleukin-1 | 23 | 2002 | 455 | 1.260 |
Why?
|
| Microtubule-Associated Proteins | 3 | 2018 | 529 | 1.230 |
Why?
|
| Anthracyclines | 5 | 2024 | 331 | 1.210 |
Why?
|
| Etoposide | 12 | 2008 | 873 | 1.160 |
Why?
|
| Exosomes | 2 | 2020 | 256 | 1.160 |
Why?
|
| Animals | 101 | 2023 | 59490 | 1.150 |
Why?
|
| Chemokine CXCL12 | 3 | 2013 | 132 | 1.150 |
Why?
|
| Benzamides | 6 | 2014 | 1834 | 1.030 |
Why?
|
| Hodgkin Disease | 2 | 2024 | 1435 | 1.010 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 3 | 2013 | 38 | 1.000 |
Why?
|
| Cell Line, Tumor | 41 | 2021 | 14560 | 0.990 |
Why?
|
| Genetic Therapy | 8 | 2014 | 1603 | 0.980 |
Why?
|
| Exercise Therapy | 3 | 2023 | 291 | 0.960 |
Why?
|
| Proto-Oncogene Proteins c-sis | 3 | 2013 | 80 | 0.940 |
Why?
|
| Liposomes | 38 | 2001 | 681 | 0.940 |
Why?
|
| Tumor Cells, Cultured | 36 | 2020 | 5378 | 0.930 |
Why?
|
| Circulating MicroRNA | 1 | 2023 | 26 | 0.930 |
Why?
|
| Pyridines | 5 | 2014 | 1243 | 0.910 |
Why?
|
| Antineoplastic Agents | 34 | 2014 | 14288 | 0.910 |
Why?
|
| Deoxycytidine | 6 | 2014 | 1360 | 0.900 |
Why?
|
| Interleukin-2 | 5 | 2020 | 842 | 0.900 |
Why?
|
| Mice, Inbred BALB C | 18 | 2021 | 2344 | 0.890 |
Why?
|
| Immunologic Factors | 9 | 2013 | 654 | 0.880 |
Why?
|
| Killer Cells, Natural | 6 | 2018 | 907 | 0.880 |
Why?
|
| Down-Regulation | 10 | 2013 | 2078 | 0.860 |
Why?
|
| Cell Movement | 16 | 2016 | 2462 | 0.820 |
Why?
|
| Transfection | 17 | 2017 | 2935 | 0.820 |
Why?
|
| MicroRNAs | 4 | 2023 | 2955 | 0.800 |
Why?
|
| Antineoplastic Agents, Phytogenic | 8 | 2013 | 856 | 0.760 |
Why?
|
| Humans | 176 | 2024 | 262255 | 0.740 |
Why?
|
| Up-Regulation | 17 | 2021 | 2450 | 0.730 |
Why?
|
| Macrophage Activation | 18 | 1995 | 146 | 0.730 |
Why?
|
| Adjuvants, Immunologic | 14 | 1999 | 661 | 0.730 |
Why?
|
| Tumor Microenvironment | 4 | 2020 | 2859 | 0.730 |
Why?
|
| Administration, Inhalation | 4 | 2014 | 286 | 0.720 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 561 | 0.710 |
Why?
|
| Apoptosis | 16 | 2021 | 7602 | 0.700 |
Why?
|
| Signal Transduction | 8 | 2020 | 11972 | 0.690 |
Why?
|
| Proto-Oncogene Protein c-fli-1 | 4 | 2014 | 45 | 0.670 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2014 | 8882 | 0.670 |
Why?
|
| Promoter Regions, Genetic | 10 | 2017 | 3076 | 0.660 |
Why?
|
| RNA-Binding Protein EWS | 4 | 2014 | 98 | 0.660 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2010 | 410 | 0.650 |
Why?
|
| Adenovirus E1A Proteins | 3 | 2005 | 157 | 0.650 |
Why?
|
| Muscle, Smooth, Vascular | 2 | 2010 | 329 | 0.640 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 32 | 0.630 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2010 | 1294 | 0.600 |
Why?
|
| Immunomodulation | 3 | 2018 | 246 | 0.590 |
Why?
|
| Neoplasm Metastasis | 15 | 2017 | 5124 | 0.580 |
Why?
|
| Cell Communication | 1 | 2020 | 504 | 0.580 |
Why?
|
| Ifosfamide | 7 | 2008 | 346 | 0.570 |
Why?
|
| Interleukin-11 Receptor alpha Subunit | 2 | 2017 | 14 | 0.560 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 7 | 2014 | 645 | 0.560 |
Why?
|
| Disease Models, Animal | 13 | 2021 | 7217 | 0.550 |
Why?
|
| Xenograft Model Antitumor Assays | 13 | 2019 | 3818 | 0.520 |
Why?
|
| Cytokines | 12 | 2023 | 2823 | 0.520 |
Why?
|
| Polyethyleneimine | 3 | 2006 | 19 | 0.510 |
Why?
|
| RNA, Small Interfering | 7 | 2013 | 2215 | 0.510 |
Why?
|
| Cell Differentiation | 9 | 2014 | 4043 | 0.500 |
Why?
|
| Cell Proliferation | 11 | 2018 | 7241 | 0.500 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 4 | 2017 | 56 | 0.490 |
Why?
|
| Macrophages | 5 | 2018 | 1313 | 0.490 |
Why?
|
| Autophagy | 2 | 2018 | 912 | 0.480 |
Why?
|
| Tumor Necrosis Factor-alpha | 14 | 1999 | 1540 | 0.470 |
Why?
|
| RNA, Messenger | 20 | 2013 | 6130 | 0.460 |
Why?
|
| Camptothecin | 3 | 2013 | 515 | 0.460 |
Why?
|
| Bone Marrow Transplantation | 4 | 2013 | 1639 | 0.450 |
Why?
|
| Oncogene Proteins, Fusion | 3 | 2014 | 754 | 0.440 |
Why?
|
| Antigens, Neoplasm | 8 | 2020 | 1505 | 0.440 |
Why?
|
| Lymphokines | 12 | 1989 | 268 | 0.440 |
Why?
|
| Isoenzymes | 4 | 2005 | 608 | 0.430 |
Why?
|
| Phenotype | 5 | 2021 | 6258 | 0.430 |
Why?
|
| Immunohistochemistry | 12 | 2018 | 7545 | 0.430 |
Why?
|
| Adolescent | 27 | 2024 | 31245 | 0.420 |
Why?
|
| Membrane Microdomains | 1 | 2012 | 81 | 0.420 |
Why?
|
| Drug Carriers | 17 | 2000 | 327 | 0.410 |
Why?
|
| Neoplasm Transplantation | 11 | 2016 | 1516 | 0.410 |
Why?
|
| Receptors, CXCR4 | 1 | 2013 | 270 | 0.400 |
Why?
|
| Flow Cytometry | 10 | 2014 | 3022 | 0.400 |
Why?
|
| Neovascularization, Physiologic | 2 | 2010 | 346 | 0.400 |
Why?
|
| Aerosols | 7 | 2010 | 158 | 0.390 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2013 | 3632 | 0.390 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1024 | 0.390 |
Why?
|
| Recombinant Proteins | 15 | 2011 | 2915 | 0.380 |
Why?
|
| RANK Ligand | 2 | 2009 | 119 | 0.380 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2013 | 612 | 0.370 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2013 | 406 | 0.370 |
Why?
|
| Mice, Inbred C3H | 5 | 2020 | 380 | 0.350 |
Why?
|
| Interferon-gamma | 14 | 2001 | 1148 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2008 | 271 | 0.340 |
Why?
|
| Alternative Splicing | 2 | 2011 | 581 | 0.330 |
Why?
|
| Blotting, Western | 7 | 2013 | 3529 | 0.330 |
Why?
|
| Cell Survival | 9 | 2021 | 3042 | 0.330 |
Why?
|
| Young Adult | 10 | 2024 | 21497 | 0.330 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1250 | 0.330 |
Why?
|
| Osteolysis | 1 | 2009 | 80 | 0.320 |
Why?
|
| Antigens, CD34 | 2 | 2008 | 593 | 0.320 |
Why?
|
| Cisplatin | 13 | 2008 | 2432 | 0.320 |
Why?
|
| Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2007 | 33 | 0.310 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2005 | 57 | 0.310 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2020 | 15874 | 0.310 |
Why?
|
| Neoplasms | 16 | 2020 | 15179 | 0.300 |
Why?
|
| Interleukin-1alpha | 1 | 2008 | 55 | 0.300 |
Why?
|
| Muscle, Skeletal | 3 | 2023 | 1277 | 0.300 |
Why?
|
| Physical Conditioning, Animal | 2 | 2019 | 112 | 0.300 |
Why?
|
| Oxidative Stress | 1 | 2013 | 1129 | 0.300 |
Why?
|
| Combined Modality Therapy | 12 | 2018 | 8886 | 0.290 |
Why?
|
| Endothelium, Vascular | 2 | 2008 | 875 | 0.290 |
Why?
|
| Aspergillus fumigatus | 1 | 2007 | 136 | 0.290 |
Why?
|
| Endothelial Cells | 7 | 2019 | 1046 | 0.290 |
Why?
|
| Administration, Intranasal | 5 | 2007 | 193 | 0.290 |
Why?
|
| Transcription Factors | 5 | 2016 | 5253 | 0.290 |
Why?
|
| Lung Diseases, Fungal | 1 | 2007 | 124 | 0.290 |
Why?
|
| Neoplasm Proteins | 5 | 2019 | 3233 | 0.280 |
Why?
|
| Lymphocytes | 4 | 2007 | 1228 | 0.280 |
Why?
|
| CpG Islands | 1 | 2009 | 631 | 0.280 |
Why?
|
| Mice, Transgenic | 6 | 2013 | 4126 | 0.280 |
Why?
|
| Genetic Vectors | 8 | 2009 | 1681 | 0.280 |
Why?
|
| Lung | 6 | 2013 | 3167 | 0.270 |
Why?
|
| Cyclooxygenase 2 | 1 | 2008 | 481 | 0.270 |
Why?
|
| Repressor Proteins | 1 | 2014 | 1663 | 0.270 |
Why?
|
| Receptor, ErbB-2 | 4 | 2009 | 2519 | 0.270 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 3 | 2011 | 153 | 0.270 |
Why?
|
| Plasmids | 5 | 2014 | 834 | 0.260 |
Why?
|
| RNA-Binding Proteins | 1 | 2011 | 984 | 0.260 |
Why?
|
| Aspergillosis | 1 | 2007 | 246 | 0.260 |
Why?
|
| src-Family Kinases | 1 | 2008 | 479 | 0.260 |
Why?
|
| Membrane Glycoproteins | 3 | 2006 | 1071 | 0.260 |
Why?
|
| Cell Line | 15 | 2021 | 5071 | 0.260 |
Why?
|
| Heterografts | 3 | 2017 | 734 | 0.260 |
Why?
|
| Female | 46 | 2024 | 142298 | 0.260 |
Why?
|
| Antibodies | 2 | 2007 | 833 | 0.250 |
Why?
|
| Transcription, Genetic | 8 | 2013 | 3127 | 0.250 |
Why?
|
| Immunoenzyme Techniques | 3 | 2013 | 1165 | 0.250 |
Why?
|
| Calcium-Binding Proteins | 3 | 2014 | 549 | 0.250 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2022 | 881 | 0.250 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2010 | 1268 | 0.250 |
Why?
|
| HEK293 Cells | 4 | 2020 | 1498 | 0.240 |
Why?
|
| Stem Cells | 2 | 2014 | 1206 | 0.240 |
Why?
|
| Child | 22 | 2018 | 29073 | 0.240 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2007 | 749 | 0.240 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2006 | 591 | 0.240 |
Why?
|
| Biomarkers, Tumor | 6 | 2018 | 10348 | 0.240 |
Why?
|
| Integrin alphaVbeta3 | 1 | 2004 | 45 | 0.240 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 197 | 0.230 |
Why?
|
| Male | 38 | 2019 | 123346 | 0.230 |
Why?
|
| Diphosphonates | 1 | 2005 | 261 | 0.230 |
Why?
|
| Cells, Cultured | 19 | 2009 | 5598 | 0.230 |
Why?
|
| Phosphatidylglycerols | 2 | 2001 | 33 | 0.230 |
Why?
|
| Troponin | 1 | 2023 | 92 | 0.230 |
Why?
|
| DNA-Binding Proteins | 7 | 2005 | 4787 | 0.230 |
Why?
|
| Monocytes, Activated Killer | 2 | 1993 | 2 | 0.220 |
Why?
|
| Recovery of Function | 1 | 2007 | 719 | 0.220 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 697 | 0.220 |
Why?
|
| Neurons | 1 | 2014 | 2290 | 0.220 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2021 | 1435 | 0.220 |
Why?
|
| Macrophage-Activating Factors | 12 | 1999 | 12 | 0.220 |
Why?
|
| Phosphatidylcholines | 2 | 2001 | 144 | 0.220 |
Why?
|
| T-Lymphocytes | 3 | 2020 | 3878 | 0.220 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 3317 | 0.220 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 88 | 0.220 |
Why?
|
| Peptides | 5 | 2017 | 1476 | 0.210 |
Why?
|
| Adenoviridae | 6 | 2008 | 1432 | 0.210 |
Why?
|
| Methotrexate | 6 | 2008 | 1002 | 0.210 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2008 | 1236 | 0.200 |
Why?
|
| Neoplasms, Experimental | 6 | 2018 | 745 | 0.200 |
Why?
|
| Herpes Simplex | 3 | 1990 | 94 | 0.200 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2016 | 619 | 0.200 |
Why?
|
| Technetium Tc 99m Dimercaptosuccinic Acid | 1 | 2021 | 1 | 0.200 |
Why?
|
| Organic Anion Transporters, Sodium-Independent | 1 | 2021 | 2 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2005 | 5183 | 0.200 |
Why?
|
| Cyclophosphamide | 3 | 2007 | 3081 | 0.200 |
Why?
|
| Paclitaxel | 2 | 2005 | 1998 | 0.200 |
Why?
|
| Gene Transfer Techniques | 4 | 2009 | 712 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 9 | 2014 | 4385 | 0.190 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 83 | 0.190 |
Why?
|
| Melanoma, Experimental | 2 | 2020 | 367 | 0.190 |
Why?
|
| Adult | 25 | 2023 | 78177 | 0.190 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2020 | 31 | 0.190 |
Why?
|
| Survival Analysis | 5 | 2020 | 9195 | 0.190 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2020 | 85 | 0.180 |
Why?
|
| Prognosis | 8 | 2023 | 21736 | 0.180 |
Why?
|
| Integrin alpha Chains | 1 | 2020 | 28 | 0.180 |
Why?
|
| DNA Primers | 3 | 2011 | 1395 | 0.180 |
Why?
|
| Genes, erbB-2 | 1 | 2001 | 229 | 0.180 |
Why?
|
| Child, Preschool | 10 | 2018 | 16222 | 0.180 |
Why?
|
| Sarcoma, Experimental | 1 | 2020 | 68 | 0.180 |
Why?
|
| Macrophages, Alveolar | 1 | 2020 | 69 | 0.180 |
Why?
|
| Drug Synergism | 6 | 2006 | 1316 | 0.180 |
Why?
|
| Sp7 Transcription Factor | 3 | 2016 | 27 | 0.180 |
Why?
|
| Feasibility Studies | 4 | 2017 | 2302 | 0.180 |
Why?
|
| Sarcopenia | 1 | 2021 | 110 | 0.180 |
Why?
|
| Membrane Proteins | 1 | 2010 | 2812 | 0.180 |
Why?
|
| Imidazoles | 1 | 2005 | 1004 | 0.180 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 323 | 0.180 |
Why?
|
| Health Status | 1 | 2023 | 604 | 0.170 |
Why?
|
| Heart Function Tests | 1 | 2019 | 72 | 0.170 |
Why?
|
| Leukocytes, Mononuclear | 4 | 1995 | 706 | 0.170 |
Why?
|
| Alpha Particles | 1 | 2019 | 26 | 0.170 |
Why?
|
| Capillary Permeability | 1 | 2019 | 114 | 0.170 |
Why?
|
| Stroke Volume | 1 | 2021 | 575 | 0.160 |
Why?
|
| In Vitro Techniques | 9 | 2020 | 1615 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2009 | 2671 | 0.160 |
Why?
|
| Proteoglycans | 2 | 2011 | 255 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2016 | 3891 | 0.160 |
Why?
|
| Dendritic Cells | 2 | 2020 | 1088 | 0.160 |
Why?
|
| Chemokine CCL2 | 2 | 1996 | 196 | 0.160 |
Why?
|
| Neuroblastoma | 2 | 2020 | 683 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2017 | 1595 | 0.160 |
Why?
|
| Radium | 1 | 2019 | 93 | 0.150 |
Why?
|
| Diet Therapy | 1 | 2017 | 53 | 0.150 |
Why?
|
| RNA, Long Noncoding | 2 | 2014 | 601 | 0.150 |
Why?
|
| Osteoprotegerin | 2 | 2008 | 24 | 0.150 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 621 | 0.150 |
Why?
|
| Gene Expression Regulation | 3 | 1999 | 4027 | 0.140 |
Why?
|
| Mammary Neoplasms, Experimental | 2 | 2014 | 494 | 0.140 |
Why?
|
| Melanoma | 15 | 1999 | 5319 | 0.140 |
Why?
|
| RNA Interference | 3 | 2012 | 1412 | 0.140 |
Why?
|
| Osteoclasts | 2 | 2009 | 161 | 0.140 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1996 | 57 | 0.140 |
Why?
|
| Interleukin-27 | 1 | 2016 | 8 | 0.140 |
Why?
|
| Cell Growth Processes | 2 | 2008 | 342 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 7 | 2020 | 6927 | 0.140 |
Why?
|
| Blotting, Northern | 4 | 2002 | 672 | 0.140 |
Why?
|
| GPI-Linked Proteins | 2 | 2013 | 224 | 0.140 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 762 | 0.140 |
Why?
|
| Survival Rate | 7 | 2013 | 12239 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 1750 | 0.130 |
Why?
|
| Chemotaxis | 2 | 2007 | 139 | 0.130 |
Why?
|
| Blood Pressure | 1 | 2021 | 1466 | 0.130 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2006 | 157 | 0.130 |
Why?
|
| Exercise | 1 | 2023 | 1187 | 0.130 |
Why?
|
| Lipopolysaccharides | 8 | 1991 | 559 | 0.130 |
Why?
|
| Disease-Free Survival | 7 | 2010 | 10021 | 0.130 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 696 | 0.130 |
Why?
|
| Nursing Research | 1 | 1995 | 18 | 0.130 |
Why?
|
| Histone Acetyltransferases | 1 | 2017 | 410 | 0.130 |
Why?
|
| Antigens, CD | 1 | 2020 | 1382 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2016 | 3549 | 0.130 |
Why?
|
| Osteogenesis | 1 | 2016 | 259 | 0.130 |
Why?
|
| Vaccines | 1 | 2020 | 392 | 0.120 |
Why?
|
| Physicians, Family | 1 | 1995 | 55 | 0.120 |
Why?
|
| Cell Separation | 7 | 2004 | 610 | 0.120 |
Why?
|
| Base Sequence | 3 | 2014 | 4887 | 0.120 |
Why?
|
| Cell Division | 7 | 2001 | 2467 | 0.120 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2014 | 1063 | 0.120 |
Why?
|
| Microscopy, Fluorescence | 2 | 2014 | 767 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2013 | 3983 | 0.120 |
Why?
|
| Chemotactic Factors | 1 | 1994 | 42 | 0.120 |
Why?
|
| Transcription Factor HES-1 | 1 | 2014 | 49 | 0.120 |
Why?
|
| Cell Adhesion | 3 | 2004 | 1001 | 0.120 |
Why?
|
| Biomarkers | 2 | 2023 | 5056 | 0.120 |
Why?
|
| HeLa Cells | 1 | 2017 | 1642 | 0.120 |
Why?
|
| Autophagy-Related Protein 5 | 1 | 2013 | 43 | 0.120 |
Why?
|
| Buthionine Sulfoximine | 1 | 2013 | 41 | 0.120 |
Why?
|
| Drug Interactions | 4 | 2005 | 555 | 0.120 |
Why?
|
| Benzylamines | 1 | 2013 | 103 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2010 | 1448 | 0.120 |
Why?
|
| Caspases | 2 | 2013 | 662 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2013 | 4945 | 0.110 |
Why?
|
| Tissue Distribution | 4 | 2021 | 877 | 0.110 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2013 | 131 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 1487 | 0.110 |
Why?
|
| Gene Expression | 2 | 2018 | 3563 | 0.110 |
Why?
|
| Heterocyclic Compounds | 1 | 2013 | 119 | 0.110 |
Why?
|
| Actins | 2 | 2013 | 605 | 0.110 |
Why?
|
| Coronary Artery Disease | 1 | 2021 | 1014 | 0.110 |
Why?
|
| Gene Knockdown Techniques | 2 | 2013 | 1077 | 0.110 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 329 | 0.110 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2009 | 584 | 0.110 |
Why?
|
| Vimentin | 1 | 2014 | 252 | 0.110 |
Why?
|
| Ibuprofen | 1 | 1993 | 56 | 0.110 |
Why?
|
| Actin Cytoskeleton | 1 | 2013 | 82 | 0.110 |
Why?
|
| Salvage Therapy | 4 | 2008 | 2059 | 0.110 |
Why?
|
| Pharmaceutical Vehicles | 2 | 2009 | 15 | 0.110 |
Why?
|
| Treatment Outcome | 9 | 2020 | 33032 | 0.110 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2013 | 110 | 0.110 |
Why?
|
| Retroviridae Proteins | 2 | 1989 | 20 | 0.110 |
Why?
|
| Cell Cycle | 4 | 2002 | 2085 | 0.110 |
Why?
|
| Pediatric Obesity | 1 | 2017 | 365 | 0.110 |
Why?
|
| Transplantation, Heterologous | 3 | 2016 | 1077 | 0.110 |
Why?
|
| Drug Resistance, Multiple | 3 | 1999 | 205 | 0.110 |
Why?
|
| Time Factors | 9 | 2013 | 12984 | 0.110 |
Why?
|
| Gene Silencing | 2 | 2013 | 835 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 507 | 0.110 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 13669 | 0.100 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 1396 | 0.100 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2011 | 19 | 0.100 |
Why?
|
| Interleukins | 3 | 2001 | 327 | 0.100 |
Why?
|
| Colony-Stimulating Factors | 2 | 1990 | 82 | 0.100 |
Why?
|
| Injections, Intravenous | 3 | 2009 | 576 | 0.100 |
Why?
|
| Clinical Trials as Topic | 4 | 1995 | 3755 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 1995 | 573 | 0.100 |
Why?
|
| Gene Products, gag | 2 | 1990 | 36 | 0.100 |
Why?
|
| Desmin | 1 | 2011 | 61 | 0.100 |
Why?
|
| Species Specificity | 2 | 2010 | 774 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2007 | 1417 | 0.100 |
Why?
|
| Tumor Burden | 3 | 2020 | 1991 | 0.100 |
Why?
|
| Heart | 1 | 2018 | 1227 | 0.100 |
Why?
|
| Immunotherapy | 7 | 2020 | 3348 | 0.100 |
Why?
|
| H-2 Antigens | 1 | 2010 | 39 | 0.100 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2017 | 566 | 0.100 |
Why?
|
| Electroporation | 1 | 2011 | 126 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2013 | 10067 | 0.100 |
Why?
|
| Antigens | 1 | 2011 | 292 | 0.090 |
Why?
|
| Leukocyte Count | 4 | 2007 | 683 | 0.090 |
Why?
|
| Protein Transport | 1 | 2013 | 734 | 0.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2014 | 994 | 0.090 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2010 | 21 | 0.090 |
Why?
|
| Dogs | 4 | 2014 | 1157 | 0.090 |
Why?
|
| Breast Neoplasms | 6 | 2005 | 15709 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2013 | 1760 | 0.090 |
Why?
|
| Receptors, CXCR3 | 1 | 2009 | 36 | 0.090 |
Why?
|
| Lithium | 1 | 1989 | 72 | 0.090 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2010 | 205 | 0.090 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2011 | 511 | 0.090 |
Why?
|
| Interleukin-4 | 1 | 1990 | 284 | 0.090 |
Why?
|
| Chlorides | 1 | 1989 | 139 | 0.090 |
Why?
|
| Simplexvirus | 1 | 1990 | 157 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2010 | 301 | 0.090 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1221 | 0.090 |
Why?
|
| Biological Transport | 2 | 2021 | 598 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1995 | 1493 | 0.080 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2014 | 505 | 0.080 |
Why?
|
| Middle Aged | 14 | 2019 | 86544 | 0.080 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2014 | 608 | 0.080 |
Why?
|
| Amsacrine | 3 | 1996 | 61 | 0.080 |
Why?
|
| Deltaretrovirus | 2 | 1987 | 7 | 0.080 |
Why?
|
| Cytotoxicity Tests, Immunologic | 4 | 1993 | 84 | 0.080 |
Why?
|
| Dinoprostone | 1 | 1990 | 208 | 0.080 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 1389 | 0.080 |
Why?
|
| Ataxins | 1 | 2008 | 91 | 0.080 |
Why?
|
| Extracellular Fluid | 1 | 2008 | 19 | 0.080 |
Why?
|
| Receptor, Notch1 | 1 | 2010 | 217 | 0.080 |
Why?
|
| Protein Isoforms | 2 | 2008 | 836 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 7566 | 0.080 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 1139 | 0.080 |
Why?
|
| Kinetics | 5 | 1996 | 2041 | 0.080 |
Why?
|
| DNA Modification Methylases | 1 | 2009 | 173 | 0.080 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 662 | 0.080 |
Why?
|
| Transduction, Genetic | 3 | 2009 | 463 | 0.080 |
Why?
|
| Binding Sites | 2 | 2013 | 2170 | 0.080 |
Why?
|
| Receptors, Chemokine | 1 | 2008 | 116 | 0.080 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2007 | 25 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2008 | 157 | 0.080 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 1987 | 36 | 0.080 |
Why?
|
| Thrombospondins | 1 | 2007 | 22 | 0.080 |
Why?
|
| Ataxin-1 | 1 | 2008 | 147 | 0.080 |
Why?
|
| Bone Resorption | 1 | 2008 | 137 | 0.080 |
Why?
|
| Introns | 1 | 2009 | 430 | 0.080 |
Why?
|
| Growth Substances | 1 | 1988 | 298 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2016 | 2362 | 0.070 |
Why?
|
| Sp1 Transcription Factor | 1 | 2008 | 188 | 0.070 |
Why?
|
| DNA, Antisense | 1 | 2006 | 42 | 0.070 |
Why?
|
| Peptide Fragments | 2 | 1990 | 1265 | 0.070 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 739 | 0.070 |
Why?
|
| Infusions, Intravenous | 4 | 1993 | 1379 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2014 | 1397 | 0.070 |
Why?
|
| RNA | 2 | 2007 | 1010 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2006 | 34 | 0.070 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 623 | 0.070 |
Why?
|
| Viral Envelope Proteins | 1 | 1987 | 207 | 0.070 |
Why?
|
| Laminin | 1 | 2006 | 196 | 0.070 |
Why?
|
| Oligopeptides | 2 | 2004 | 425 | 0.070 |
Why?
|
| Injections, Intralesional | 1 | 2006 | 162 | 0.070 |
Why?
|
| Luciferases, Firefly | 1 | 2005 | 39 | 0.070 |
Why?
|
| Mutation | 3 | 2023 | 15173 | 0.070 |
Why?
|
| Tumor Stem Cell Assay | 2 | 1996 | 232 | 0.070 |
Why?
|
| Microfilament Proteins | 1 | 2009 | 488 | 0.070 |
Why?
|
| Oncolytic Viruses | 1 | 2008 | 183 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2001 | 666 | 0.070 |
Why?
|
| Platelet Count | 1 | 2007 | 490 | 0.070 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2001 | 603 | 0.070 |
Why?
|
| Quality of Life | 1 | 2020 | 4582 | 0.070 |
Why?
|
| Brain Neoplasms | 6 | 2014 | 4838 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 222 | 0.070 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 194 | 0.070 |
Why?
|
| Aged | 8 | 2019 | 70365 | 0.060 |
Why?
|
| Glioblastoma | 1 | 1996 | 1799 | 0.060 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2005 | 46 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2005 | 190 | 0.060 |
Why?
|
| Oncolytic Virotherapy | 1 | 2008 | 252 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2005 | 226 | 0.060 |
Why?
|
| Cadherins | 1 | 2008 | 663 | 0.060 |
Why?
|
| Thymidine | 1 | 2004 | 151 | 0.060 |
Why?
|
| Skin Neoplasms | 2 | 1998 | 4655 | 0.060 |
Why?
|
| Drug Combinations | 1 | 2006 | 621 | 0.060 |
Why?
|
| Spinal Cord Compression | 1 | 1986 | 151 | 0.060 |
Why?
|
| Piperazines | 2 | 2010 | 2098 | 0.060 |
Why?
|
| Neutrophils | 1 | 1989 | 834 | 0.060 |
Why?
|
| Vitronectin | 1 | 2004 | 22 | 0.060 |
Why?
|
| Receptors, Vitronectin | 1 | 2004 | 24 | 0.060 |
Why?
|
| Disease Progression | 3 | 2014 | 6696 | 0.060 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 6932 | 0.060 |
Why?
|
| Injections, Intraperitoneal | 2 | 2002 | 196 | 0.060 |
Why?
|
| beta-Galactosidase | 1 | 2003 | 210 | 0.060 |
Why?
|
| Integrin alpha4 | 1 | 2003 | 24 | 0.060 |
Why?
|
| Bone Marrow Diseases | 2 | 1997 | 174 | 0.060 |
Why?
|
| Sarcoma, Kaposi | 1 | 1985 | 187 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2005 | 798 | 0.060 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2004 | 290 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 2334 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 446 | 0.060 |
Why?
|
| Collagen | 1 | 2006 | 737 | 0.060 |
Why?
|
| Fibrosis | 2 | 1997 | 767 | 0.060 |
Why?
|
| Anoikis | 1 | 2003 | 63 | 0.050 |
Why?
|
| Immunity, Innate | 2 | 1990 | 677 | 0.050 |
Why?
|
| Pneumonectomy | 1 | 2008 | 832 | 0.050 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1985 | 361 | 0.050 |
Why?
|
| Radioisotopes | 2 | 2019 | 177 | 0.050 |
Why?
|
| Connective Tissue | 1 | 2022 | 41 | 0.050 |
Why?
|
| Azacitidine | 1 | 2009 | 1149 | 0.050 |
Why?
|
| Trastuzumab | 1 | 2005 | 697 | 0.050 |
Why?
|
| Fever | 2 | 1997 | 498 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2022 | 38009 | 0.050 |
Why?
|
| Trans-Activators | 1 | 2009 | 1557 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2013 | 14913 | 0.050 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 29996 | 0.050 |
Why?
|
| Rats | 3 | 2007 | 6107 | 0.050 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1986 | 393 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 143 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2005 | 746 | 0.050 |
Why?
|
| Ribose | 1 | 2021 | 32 | 0.050 |
Why?
|
| Kupffer Cells | 2 | 1993 | 41 | 0.050 |
Why?
|
| Hematopoietic Cell Growth Factors | 1 | 2001 | 38 | 0.050 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 2325 | 0.050 |
Why?
|
| Interleukin-8 | 2 | 1994 | 520 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2021 | 114 | 0.050 |
Why?
|
| Salicylates | 1 | 1981 | 58 | 0.050 |
Why?
|
| Dexamethasone | 2 | 1996 | 1450 | 0.050 |
Why?
|
| Sex Factors | 1 | 2007 | 2156 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2009 | 1879 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2001 | 158 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 1900 | 0.050 |
Why?
|
| Oxygen | 1 | 1985 | 755 | 0.050 |
Why?
|
| Drug Evaluation | 2 | 1992 | 424 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 170 | 0.050 |
Why?
|
| Feedback | 1 | 2021 | 206 | 0.050 |
Why?
|
| Heart Neoplasms | 1 | 2003 | 215 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 1492 | 0.050 |
Why?
|
| Cell Membrane | 3 | 1990 | 855 | 0.050 |
Why?
|
| Phagocytosis | 4 | 1988 | 260 | 0.050 |
Why?
|
| Immunoblotting | 2 | 1993 | 882 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 6046 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6223 | 0.050 |
Why?
|
| Cross-Priming | 1 | 2020 | 39 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 1981 | 674 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 445 | 0.050 |
Why?
|
| Neutropenia | 2 | 1997 | 965 | 0.040 |
Why?
|
| Infant | 5 | 2009 | 13289 | 0.040 |
Why?
|
| Hydrocortisone | 1 | 1981 | 389 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2005 | 1529 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 3263 | 0.040 |
Why?
|
| Antigen Presentation | 1 | 2020 | 272 | 0.040 |
Why?
|
| Cytosol | 2 | 1990 | 237 | 0.040 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 37 | 0.040 |
Why?
|
| Drug Design | 1 | 2001 | 379 | 0.040 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2014 | 4768 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2005 | 1551 | 0.040 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2023 | 802 | 0.040 |
Why?
|
| Consensus | 1 | 2022 | 1005 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2021 | 622 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2009 | 3482 | 0.040 |
Why?
|
| Protein Kinase C | 2 | 1990 | 397 | 0.040 |
Why?
|
| Capillary Leak Syndrome | 1 | 1997 | 14 | 0.040 |
Why?
|
| Mitochondria | 2 | 2021 | 1282 | 0.040 |
Why?
|
| Vinblastine | 1 | 1999 | 453 | 0.040 |
Why?
|
| Retroviridae | 2 | 2009 | 323 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2010 | 3538 | 0.040 |
Why?
|
| Respiration Disorders | 1 | 1997 | 45 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2022 | 981 | 0.040 |
Why?
|
| Femoral Neoplasms | 1 | 1997 | 62 | 0.040 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2017 | 22 | 0.040 |
Why?
|
| Autocrine Communication | 1 | 2017 | 84 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1989 | 227 | 0.040 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2017 | 32 | 0.040 |
Why?
|
| Age Factors | 1 | 2007 | 5384 | 0.040 |
Why?
|
| Core Binding Factor Alpha 1 Subunit | 1 | 2016 | 28 | 0.040 |
Why?
|
| Alopecia | 1 | 1997 | 127 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2017 | 5672 | 0.040 |
Why?
|
| Restriction Mapping | 1 | 1996 | 260 | 0.040 |
Why?
|
| Hot Temperature | 2 | 1990 | 281 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2005 | 2023 | 0.040 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 1996 | 122 | 0.030 |
Why?
|
| Polymyxin B | 3 | 1985 | 53 | 0.030 |
Why?
|
| Receptors, Interleukin | 1 | 2016 | 97 | 0.030 |
Why?
|
| Hypotension | 1 | 1997 | 210 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 4556 | 0.030 |
Why?
|
| Gangliosides | 1 | 1996 | 94 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2016 | 135 | 0.030 |
Why?
|
| Job Description | 1 | 1995 | 16 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2008 | 4980 | 0.030 |
Why?
|
| Immunity, Cellular | 2 | 1989 | 419 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 1999 | 889 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2021 | 4809 | 0.030 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 1995 | 70 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 1998 | 1363 | 0.030 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 1995 | 220 | 0.030 |
Why?
|
| Genotype | 2 | 2016 | 4104 | 0.030 |
Why?
|
| Liver | 1 | 2004 | 2904 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2014 | 190 | 0.030 |
Why?
|
| Proteomics | 1 | 2021 | 1386 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 1995 | 544 | 0.030 |
Why?
|
| Half-Life | 1 | 1994 | 258 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 1994 | 154 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2014 | 166 | 0.030 |
Why?
|
| Cell Death | 1 | 1996 | 672 | 0.030 |
Why?
|
| Integrins | 1 | 1995 | 261 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 630 | 0.030 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1994 | 154 | 0.030 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2019 | 845 | 0.030 |
Why?
|
| Serum Albumin, Bovine | 2 | 1990 | 83 | 0.030 |
Why?
|
| Neopterin | 1 | 1992 | 13 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 1997 | 587 | 0.030 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 234 | 0.030 |
Why?
|
| Acetylation | 1 | 2013 | 511 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 1247 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2013 | 626 | 0.030 |
Why?
|
| Carcinoma | 2 | 1999 | 2582 | 0.030 |
Why?
|
| Safety | 1 | 2013 | 464 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 904 | 0.020 |
Why?
|
| Prospective Studies | 2 | 2022 | 12923 | 0.020 |
Why?
|
| Remission Induction | 1 | 1997 | 3584 | 0.020 |
Why?
|
| Splenic Neoplasms | 1 | 1992 | 119 | 0.020 |
Why?
|
| Nucleocapsid Proteins | 1 | 1990 | 12 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 992 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2014 | 730 | 0.020 |
Why?
|
| Drosophila | 1 | 1996 | 839 | 0.020 |
Why?
|
| Agammaglobulinemia | 1 | 1990 | 45 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1996 | 1557 | 0.020 |
Why?
|
| Phytohemagglutinins | 1 | 1990 | 70 | 0.020 |
Why?
|
| Vaccinia | 1 | 1990 | 11 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2014 | 474 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2014 | 938 | 0.020 |
Why?
|
| Lithium Chloride | 1 | 1989 | 28 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1995 | 1905 | 0.020 |
Why?
|
| Biotechnology | 1 | 1990 | 63 | 0.020 |
Why?
|
| RNA, Antisense | 1 | 2009 | 68 | 0.020 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1989 | 14 | 0.020 |
Why?
|
| Risk Factors | 1 | 2007 | 17622 | 0.020 |
Why?
|
| Sirolimus | 1 | 2014 | 818 | 0.020 |
Why?
|
| Kidney Neoplasms | 2 | 1995 | 3018 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 2321 | 0.020 |
Why?
|
| Leukocytosis | 1 | 1989 | 111 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1990 | 625 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 1995 | 1668 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1989 | 94 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 1994 | 1031 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1990 | 566 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 1989 | 300 | 0.020 |
Why?
|
| Hybrid Cells | 1 | 1989 | 111 | 0.020 |
Why?
|
| Acetamides | 1 | 2009 | 112 | 0.020 |
Why?
|
| Isoquinolines | 1 | 1989 | 116 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 1992 | 526 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2017 | 1423 | 0.020 |
Why?
|
| CD28 Antigens | 1 | 2009 | 202 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2013 | 596 | 0.020 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 1990 | 240 | 0.020 |
Why?
|
| Pediatrics | 1 | 2017 | 1130 | 0.020 |
Why?
|
| DNA | 1 | 1996 | 2683 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1989 | 276 | 0.020 |
Why?
|
| Depression, Chemical | 1 | 1987 | 52 | 0.020 |
Why?
|
| Endotoxins | 2 | 1985 | 96 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 2280 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2009 | 315 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 1990 | 573 | 0.020 |
Why?
|
| Lymphocyte Activation | 2 | 1993 | 1690 | 0.020 |
Why?
|
| DNA, Viral | 1 | 1990 | 675 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1989 | 311 | 0.020 |
Why?
|
| Temperature | 1 | 1989 | 508 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1987 | 348 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2007 | 261 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2008 | 183 | 0.020 |
Why?
|
| Virus Replication | 1 | 1990 | 706 | 0.020 |
Why?
|
| Myelography | 1 | 1986 | 16 | 0.020 |
Why?
|
| Histones | 1 | 2013 | 1462 | 0.020 |
Why?
|
| HIV | 1 | 1987 | 229 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 1986 | 254 | 0.020 |
Why?
|
| Paresthesia | 1 | 1986 | 33 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2010 | 1665 | 0.020 |
Why?
|
| Epidural Space | 1 | 1986 | 42 | 0.020 |
Why?
|
| Prostaglandins E | 2 | 1985 | 23 | 0.020 |
Why?
|
| Salmonella typhi | 1 | 1985 | 15 | 0.020 |
Why?
|
| Thymoma | 1 | 1989 | 247 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 1097 | 0.020 |
Why?
|
| Indomethacin | 2 | 1985 | 91 | 0.020 |
Why?
|
| Catalase | 1 | 1985 | 70 | 0.020 |
Why?
|
| Indium | 1 | 1985 | 20 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4976 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2009 | 1865 | 0.020 |
Why?
|
| Kidney | 2 | 1984 | 2144 | 0.020 |
Why?
|
| Superoxides | 1 | 1985 | 209 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 1980 | 4660 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 1985 | 216 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1989 | 600 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1985 | 267 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2005 | 518 | 0.010 |
Why?
|
| Exons | 1 | 2007 | 1326 | 0.010 |
Why?
|
| Granuloma | 1 | 1985 | 155 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1984 | 137 | 0.010 |
Why?
|
| Calcium | 1 | 2009 | 1545 | 0.010 |
Why?
|
| Cytochromes c | 1 | 2003 | 118 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2007 | 1111 | 0.010 |
Why?
|
| Adenocarcinoma | 2 | 1993 | 7793 | 0.010 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2009 | 1145 | 0.010 |
Why?
|
| Aminoacridines | 1 | 1982 | 23 | 0.010 |
Why?
|
| Prostate | 1 | 2008 | 1090 | 0.010 |
Why?
|
| Endocytosis | 1 | 1983 | 224 | 0.010 |
Why?
|
| Dactinomycin | 1 | 1982 | 143 | 0.010 |
Why?
|
| Proteins | 1 | 1990 | 1953 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1986 | 510 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 2504 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1980 | 97 | 0.010 |
Why?
|
| X-Rays | 1 | 1980 | 145 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 1981 | 727 | 0.010 |
Why?
|
| Particle Size | 1 | 2000 | 186 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 591 | 0.010 |
Why?
|
| Melphalan | 1 | 1982 | 834 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1996 | 5100 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1981 | 465 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 7719 | 0.010 |
Why?
|
| Aspirin | 1 | 1981 | 455 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8228 | 0.010 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 1996 | 83 | 0.010 |
Why?
|
| Immunotherapy, Active | 1 | 1996 | 46 | 0.010 |
Why?
|
| Leukemia | 1 | 2005 | 1633 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1996 | 171 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 5539 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1996 | 823 | 0.010 |
Why?
|
| Immune Sera | 1 | 1993 | 145 | 0.010 |
Why?
|
| Glioma | 1 | 1983 | 1940 | 0.010 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 1990 | 15 | 0.010 |
Why?
|
| Warts | 1 | 1990 | 19 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2008 | 5778 | 0.010 |
Why?
|
| Hand Dermatoses | 1 | 1990 | 25 | 0.010 |
Why?
|
| Arginine | 1 | 1993 | 498 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1990 | 72 | 0.010 |
Why?
|
| Acute-Phase Proteins | 1 | 1989 | 77 | 0.010 |
Why?
|
| Skin Tests | 1 | 1989 | 96 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 1993 | 644 | 0.010 |
Why?
|
| Hematopoiesis | 1 | 1992 | 562 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1990 | 935 | 0.010 |
Why?
|
| Immunologic Memory | 1 | 1989 | 374 | 0.000 |
Why?
|
| Pronase | 1 | 1985 | 5 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1993 | 2802 | 0.000 |
Why?
|
| Pulmonary Alveoli | 1 | 1985 | 210 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1990 | 4231 | 0.000 |
Why?
|
| Astrocytoma | 1 | 1987 | 322 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1990 | 6062 | 0.000 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1983 | 219 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1990 | 2360 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1987 | 1306 | 0.000 |
Why?
|